Impact of polymorphisms of the major histocompatibility complex classÂ II, interleukin-10, tumor necrosis factor-Î± and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophiliaÂ A-Reference-Cited by-同舟云学术

Impact of polymorphisms of the major histocompatibility complex classÂ II, interleukin-10, tumor necrosis factor-Î± and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophiliaÂ A

Published:2009-12 Issue:12 Volume:7 Page:2006-2015
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:

Author:

PAVLOVA A.,DELEV D.,LACROIX-DESMAZES S.,SCHWAAB R.,MENDE M.,FIMMERS R.,ASTERMARK J.,OLDENBURG J.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1538-7836.2009.03636.x/fullpdf

Reference38 articles.

1. The epidemiology of inhibitors in hemophiliaÂ A: a systematic review;Wight;Haemophilia,2003

2. Inhibitors in hemophiliaÂ A: mechanisms of inhibition, management and perspectives;Ananyeva;Blood Coagul Fibrinolysis,2004

3. Environmental and genetic factors influencing inhibitor development;Oldenburg;Semin Hematol,2004

4. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophiliaÂ A;Gouw;J Thromb Haemost,2007

5. Recombinant versus plasma-derived factorÂ VIII products and the development of inhibitors in previously untreated patients with severe hemophiliaÂ A: the CANAL cohort study;Gouw;Blood,2007

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Marginal Zone B Cells Represent a Conserved Initiating Player in the Immune Response to Factor VIII in Hemophilia A Mice;Thrombosis and Haemostasis;2024-07-16

2. A Rare Case of Hemophilia: Acquired Factor VIII Deficiency;Cureus;2024-06-14

3. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A;Blood Advances;2024-05-30

4. Genetic predictors for FVIII inhibitors formation in a Greek population of children with severe haemophilia A exclusively treated with recombinant concentrates;Haemophilia;2024-04-10

5. Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?;Haemophilia;2024-03-27